New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Kaklamani and Dr. O’Regan

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Kaklamani and Dr. O’ReganПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Meisel & Dr. SolimanПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Bagegni & Dr. GradisharПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Irene and Dr. VogelПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Mahtani & Dr. SchwartzbergПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Kevin KalinskyПодробнее

Dr. O’Regan on Prognostic Value of pCR in HER2+ Breast CancerПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Reshma MahtaniПодробнее

Dr. O'Regan on Future of Chemotherapy in Breast CancerПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Traina & Dr. CareyПодробнее

What EMERALD Phase III trial could mean for breast cancer patients | Virginia Kaklamani, MDПодробнее

APHINITY Trial for HER2+ Breast CancerПодробнее

Dr. O'Regan on Emerging CDK4/6 Combinations in Breast CancerПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Hope S. RugoПодробнее

Dr. Varella on the Results of MONALEESA-7 in HR+/HER2- Breast CancerПодробнее

Dr. Kaklamani Discusses Bone Health in Women With Breast CancerПодробнее

Navigating the Expanding Treatment Arsenal for ER+/HER2- Breast CancerПодробнее

Dr. Tolaney on the Current Treatment Landscape for HER2+ Breast CancerПодробнее

Optimizing HER2-Positive Breast Cancer Therapy: Balancing Efficacy and ToxicityПодробнее